Guimarães A, Machado A, Carvalho S, Alaiz H, Vieira L, Abecasis M
BMT Unit, Instituto Português de Oncologia, Lisbon, Portugal.
Bone Marrow Transplant. 1998 Sep;22(6):595-7. doi: 10.1038/sj.bmt.1701382.
We report the case of a 44-year-old male who relapsed in accelerated phase chronic myeloid leukemia 10 years after a successful bone marrow transplantation from his HLA-identical brother, and 3 years after 12 months treatment with interferon-alpha (IFN-alpha) for chronic active hepatitis C (CAH). The patient was infused with G-CSF-primed peripheral blood cells (PBSC) from the original bone marrow donor and a full donor reconstitution, with no detectable molecular disease, was obtained within 4 months without clinical aplasia or GVHD, nor help from other forms of chemotherapy or use of biological response modifiers. We speculate that IFN-alpha for CAH delayed the onset of a clinical recurrence of chronic myeloid leukemia and that in advanced disease PBSCs can provide an advantageous alternative to donor lymphocyte infusion (DLI).
我们报告了一例44岁男性病例,该患者在接受来自其HLA配型相合的兄弟的成功骨髓移植10年后,慢性髓性白血病加速期复发,且在因慢性活动性丙型肝炎(CAH)接受12个月的α干扰素(IFN-α)治疗3年后复发。患者输注了来自原骨髓供体的经G-CSF动员的外周血单个核细胞(PBSC),4个月内实现了完全供体重建,未检测到分子学疾病,期间无临床再生障碍或移植物抗宿主病(GVHD),也未借助其他形式的化疗或使用生物反应调节剂。我们推测,用于CAH的IFN-α延迟了慢性髓性白血病临床复发的发生,并且在晚期疾病中,PBSC可为供体淋巴细胞输注(DLI)提供一种有利的替代方案。